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It is now a universally acknowledged fact that maggot therapy can be used successfully to treat chronic,
long-standing, infected wounds, which have previously failed to respond to conventional treatment.
Such wounds are typically characterized by the presence of necrotic tissue, underlying infection and
poor healing. Maggot therapy employs the use of freshly emerged, sterile larvae of the common green-
bottle fly, Phaenicia (Lucilia) sericata, and is a form of artificially induced myiasis in a controlled clin-
ical situation. In this review article, we will discuss the role of maggots and their preparation for clinical
use. Maggot therapy has the following three core beneficial effects on a wound: debridement, disinfec-
tion and enhanced healing. In part I we explore our current understanding of the mechanisms underlying
these effects.
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Introduction I—The Rise and Fall of
Maggot Therapy
Numerous clinical reports have been published that describe
the outstanding effects of maggot therapy, most notably on
debridement, cleansing, disinfection and healing of indolent
wounds, many of which have previously failed to respond to
conventional treatment (1–11). Current day maggot therapy,
with its multi-action approach to wound cleansing and healing,
is highly successful.
Records of maggots in wounds, however, and the recogni-
tion of improvement in the wound state as a consequence of
infestation, date back to the 16th century (12). In 1829, Baron
Dominic Larrey, Napoleon’s battlefield surgeon, described
how men had arrived at his field hospital with healing
maggot-infested wounds (13). The wounds were sustained in
battle, but,owing to the presence ofmaggots, were not infected
and showed accelerated healing. Such positive accounts were
made by many surgeons who followed, but it was William
Baer, Professor of Orthopaedic Surgery at the John Hopkins
School of Medicine in Maryland, USA, who is believed to be
the founder of modern maggot therapy (14).
It was Baer who pioneered the use of sterile maggots as a
reputable method of wound therapy, following observations
he made about the value of maggots in traumatic wounds on
the battlefield in France during World War 1. Such was the
success of Baer’s work that by the mid-1930s almost 1000
North American surgeons employed maggot therapy (15) and
by the end of the decade it was in use in over 300 hospitals
in the US and Canada. However, by 1940, a new era was dawn-
ing. This era which saw the introduction and widespread use of
antibiotics following the mass production of penicillin (16). So
despite the obvious success of maggot therapy, by the
mid-1940s it had practically disappeared from use. In Part 1
of this review, we introduce the stages involved in the wound
healing process, the advantages in the use of maggots for the
cleaning (debridement) of infected wounds, and the possible
mechanisms underlying the debridement of wounds by mag-
gots. The antimicrobial activity of maggots to treat methicillin-
resistant Staphylococcus aureus (MRSA)-infected wounds
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antibacterial activity of maggot secretions are then considered
in Part II of this review.
Review of Wounds and Events during Healing
A wound is a breach in the skin, which may allow the entry of
microorganisms, possibly leading to infection. Wound tissue
provides the rich environment necessary for the proliferation
of microbes. It is characterized by hypoxia, necrosis and often
an accompanying impaired immune response owing to subop-
timal delivery of immune effector molecules through damaged
blood vessels (17). This compromised, necrotic, sloughy tissue
provides a warm, moist and nutritive environment, perfect for
replication of colonizing bacteria. Bacterial species which
were previously harmless commensals of the human body,
most commonly on the skin, may become pathogenic in a
wound environment (18). In order for a wound to heal, it
must progress through the following four main stages of the
healing process (19): (i) the inflammatory phase where hemo-
stasis occurs and numerous inflammatory mediators are
released. Leukocytes migrate into the wound, and the bacterial
burden of the wound is decreased. (ii) The destructive phase
which sees the phagocytosis of necrotic tissue and killing of
ingestedmicrobes and foreign particles. Numerous growth fac-
tors are released during this phase. (iii) The proliferative phase
involves the formation of new capillary loops and granulation
tissue (angiogenesis), fibroplasia and the synthesis of new
matrix and collagen. (iv) The maturation phase occurs when
wound collagen is remodeled and reorganized. The wound
contracts and epithelialization occurs. These events often hap-
pens during woundhealing using adaptogens (20) (natural herb
products that increase the body’s resistance to physical, chem-
ical or biological stresses). There is considerable overlap
between the various stages, and the entire healing process
can take months to complete, with full maturation often not
achieved until a year after the wound was initiated.
Types of Wounds
Wounds can be broadly divided into two types, acute and
chronic, which exhibit significant differences in the healing
process. An acute wound is one which is usually instigated
by a sudden, solitary insult, such as a traumatic injury. Such
wounds generally proceed through the healing process in an
orderly manner. In contrast, a chronic wound, such as a leg
ulcer, is usually owing to an underlying pathological process,
such as diabetes or vascular insufficiency, which produces a
repeated and prolonged insult to the tissue, resulting in severe
damage. The chronic wound does not normally progress
through the healing process, often remaining in the inflammat-
ory, infected phase and causing much discomfort and distress
to the patient. Although maggots can be used for any kind of
purulent, sloughy wound on the skin, independent of the
underlying disease or the location on the body (21), it is in
the cleansing and healing of such chronic wounds that maggot
therapy becomes an invaluable tool.
Maggot Therapy: Selection of the Flies
Many dipteran species are capable of infesting living verte-
brate hosts (a condition termed myiasis). Maggot therapy is
essentially artificially induced myiasis, performed in a con-
trolled environment by experienced medical practitioners.
Myiasis-causing flies may be grouped into two categories as
follows: obligate and facultative parasites. Obligate parasites
require the ingestion of living tissue in order to complete their
lifecycles (22). Larvae of obligate parasites can cause severe
damage to healthy tissue and are therefore unsuitable for use
in maggot therapy. Facultative parasites are able to parasitize
living hosts if conditions are favorable, but more commonly
develop on carrion and therefore have greater potential for
therapeutic use.
Selection of a suitable fly species for use in maggot therapy
is of paramount importance, determining both the safety and
success of the treatment. It is imperative to select a species
that feeds almost exclusively on necrotic tissue. William
Baer chose the larvae of Phaenicia sericata, the common
green-bottle, as the most appropriate species for this applica-
tion and this is the species still used by practitioners today.
Phaenicia larvae are facultative parasites, unable to ingest or
significantly damage healthy human tissue (2). Infestations
of living hosts by Phaenicia do, however, occur, most com-
monly in sheep to induce an often fatal condition known as
sheep strike. Exactly why Phaenicia attack the healthy tissue
of sheep and appear unable to do the same to human tissue is
as yet unknown.
Female Flies, Eggs, Larvae and
Preparation for Clinical Use
In the wild, adult female Phaenicia lay a large number of eggs
(2000–3000) over the course of a few weeks, a necessity as
relatively few will survive to adults. The eggs are laid in
clusters directly onto the chosen food source, upon which the
emerging larvae will feed. Larval development requires a
moist environment to prevent desiccation, so larvae are gener-
ally found in nutritious, damp places such as decaying animal
corpses or moist, necrotic wounds (22). Eggs hatch within
18–24 h, depending on optimal conditions, into first instar
larvae (maggots),  1–2 mm in length, which immediately
and actively begin to feed. It is this vigorous feeding activity,
which is beneficial to an infected or necrotic wound. Maggots
feed by the extracorporeal secretion of a wide spectrum of
proteolytic enzymes that liquefy the host tissue (23–26). This
semi-digested liquid material is then ingested as a source
of nutrients. The maturing first instar larvae continue to feed
for  4–5 days, molting twice as they increase in size to
 8–10 mm, at which point they stop feeding and leave the
wound or corpse to search for a dry place in the ground where
they pupate (25). Following metamorphosis, an adult fly
emerges from the pupa. In preparation for clinical use, flies
typically oviposit onto porcine liver, and the eggs are separated
and chemically sterilized. Resultant (L1) larvae are sterile
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ensure their microbiological status (3). Larvae are then main-
tained under aseptic conditions prior to wound application.
Debridement (Wound Clearing)
Maggot therapy has the following three core beneficial effects
on a wound: debridement, disinfection and enhanced healing.
Debridement is the removal of cellular debris and non-viable
necrotic tissue from the wound bed. This is a first, essential
step before healing can commence. Removal of necrotic tissue
abolishes many of the associated bacteria and also reduces
wound odor. The removal of necrotic tissue, which acts as a
microbial substrate, may also reduce the risk of infection. Dur-
ing the inflammatory stage of wound healing host leucocytes
play an important role in debridement of wound sites, degrad-
ing damaged extracellular matrix (ECM) components through
the release of proteases. The injury is initially filled with a pro-
visional wound matrix consisting predominantly of fibrin and
fibronectin. Key proteases are involved in ECM degradation
(see below). These are released from neutrophils, macro-
phages, fibroblasts, epithelial and endothelial cells. As healing
proceeds, and new ECM constituents such as collagen, elastin
and proteoglycans are synthesized, damaged ECM is removed
by these proteases (27).
Chronic Wounds
Chronic wounds do not proceed through the normal healing
process and are typically characterized by prolonged inflam-
mation, inhibition of cell proliferation (28,29), incomplete
ECM remodeling and a failure to epithelialize (30). Over
expression and inefficient debridement of temporary ECM
components, e.g. fibronectin and fibrin, contribute to the fail-
ure of chronic wounds to heal. The entire environment of a
chronic wound must be rebalanced for wound repairto proceed
to completion, an undertaking which is unlikely to occur
without extraneous intervention and one of the explanations
as to why chronic wounds may persist for many years.
There are a number of existing methods for the debridement
of chronic wounds as described by Schultz et al. (27). These
include surgical and sharp debridement (using scalpel or
scissors to remove debris and necrotic tissue), mechanical
debridement using methods such as wet-to-dry dressings,
wound irrigation and whirlpool techniques, enzymatic debri-
dement using the application of exogenous enzymes, and
autolytic debridement using hydrogels and hydrocolloids.
Each of these techniques has associated disadvantages such
as extended treatment times, pain and mechanical damage to
underlying healthy tissue.
Maggot Debridement Therapy
The alternative is maggot therapy. Maggots debride wounds
quickly and effectively, without damage to viable tissue.
Maggots are photophobic and will naturally move into the
deep crevices that may be beyond the reach of a surgeon’s
scalpel. Reports have been published marveling at the benefits
of maggot debridement therapy (MDT) in all sorts of wounds,
including abscesses, burns, gangrenous wounds, arterial and
venous ulcers, osteomyelitis, diabetic foot ulcers and pressure
sores (7,9,31–33). One such study compared MDT with con-
servative debridement therapy for the treatment of pressure
sores (34). Here, 80% of maggot-treated wounds (n ¼ 43)
were completely debrided, while only 48% of conventionally
treated wounds (n ¼ 49) were completely debrided. Also, by
using maggots, total wound surface area decreased, whereas
during conventional debridement therapy, the total wound
area had increased (p ¼ 0.001) (34). The report concluded
that maggot therapy was a more effective and efficient way
of debriding chronic pressure sores than the conventional
treatments prescribed.
Mechanisms of MDT
How exactly maggots remove devitalized, necrotic tissue from
the wound is currently actively being investigated. Research
into the debridement mechanisms underlying maggot therapy
has revealed that maggots secrete a rich soup of digestive
enzymes while feeding, including carboxypeptidases A and B
(35), leucine aminopeptidase (35), collagenase (23,36) and
serine proteases (trypsin-like and chymotrypsin-like enzymes)
(35,37). Recently, workers in Nottingham, UK, demonstrated
in vitro a range of enzymes secreted by P. sericata larvae
(26). Four proteolytic enzymes, comprising two serine pro-
teases, a metalloproteinase and an aspartyl proteinase, were
detected, with molecular weights ranging from 20 to 40 kDa,
with activity across a wide pH range. A chymotrypsin-like
serine proteinase exhibited excellent degradation of ECM
components laminin, fibronectin, and collagen types I and III
(26), and may therefore play a significant role in the digestion
of wound matrix and effective debridement.
The mechanical action of numerous wriggling maggots in a
necrotic debris-filled wound has also been suggested in aiding
wound debridement. Maggots possess a pair of mandibles
(hooks) which assist with locomotion and attachment to tissue.
This probing and maceration of wound tissue with maggot
mouthhooks may enhance debridement (38), but these hooks
are used during feeding to disrupt membranes and thus facilit-
ate the penetration of proteolytic enzymes (3). Together, this
mechanical action and the secretion of powerful, proteolytic
enzymes may be the secret of efficient tissue debridement.
Disinfection (Introduction to
Antibiotic Activity)
For wounds to heal, and progress through stages of destruc-
tion and proliferation onto maturation, infection needs to be
eliminated. The majority of wounds are polymicrobial, hosting
a range of both anaerobic and aerobic bacteria (18,39).
Antimicrobial treatment of clinically infected and non-healing
wounds, should, therefore, encompass broad-spectrum anti-
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application of maggots to an infected wound results in
the rapid elimination of such infecting microorganisms
(2,6,40,41). The most frequently isolated pathogen from acute
and chronic wounds is Staphylococcus aureus. S. aureus is
carried innocuously by  30% of the general population (42)
[40–70% of hospital staff (43,44)], usually on the moist skin
in the nose, axillae (armpits) and perineum (groin), but can
become pathogenic when able to enter damaged skin. S. aureus
has caused great concern owing to its ability to acquire
resistance to a range of antimicrobials.
Penicillin Methicillin Resistance and MRSA
In 1948, 4 years after the widespread introduction of penicillin,
over 50% of nosocomial S. aureus were penicillin-resistant
(45) owing to the production of penicillinase (b-lactamase),
an enzyme which inactivates b-lactam antibiotics (46).
Currently, the majority (80–90%) of S. aureus are penicillin-
resistant. In 1960, a structural modification of penicillin saw
the synthetic production of methicillin, which was active
against penicillin-resistant strains of S. aureus. The launch
of methicillin, however, failed to control the proliferation of
resistant strains of bacteria and the first clinical isolate of
MRSA was reported in 1961 (47). Since then, MRSA has con-
tinued to disseminate rapidly, causing serious hospital and
community infections all over the world, with global increases
in both the numbers of infected patients and mortality. The
recent isolation of vancomycin-resistant strains of S. aureus
(VRSA) in Japan (48) severely reduces the repetoire of drugs
available to treat infections caused by resistant strains of
S. aureus.
In the literature, there is an ever increasing trend supporting
the clinical use of maggots for treating wounds infected with
MRSA (6,40,49,50). This support, initially anecdotal, was
strengthened by case studies and most recently, strong laborat-
ory evidence indicates that maggots do possess the ability to
kill clinical isolates of MRSA (51,52). As an example, Fig. 1
shows a wound 5 cm in diameter and totally covered with a
thick layer of viscous slough. One pot of larvae was applied
and left for 48 h, after which there was an immediate and
marked improvement to the wound. Two further applications
of larvae were made. At this point, only 6 days after maggot
therapy had commenced, the wound, which had not responded
to conventional treatment over 18 months, was now com-
pletely free from slough. It was filling rapidly with healthy
granulation tissue and a swab failed to detect any presence
of MRSA (Fig. 2). Larval therapy was now discontinued
and the wound continued to progress normally and healed
uneventfully (6).
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